JNJ-2056 is under clinical development by Johnson & Johnson Innovative Medicine and currently in Phase II for Tauopathies. According to GlobalData, Phase II drugs for Tauopathies does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the JNJ-2056 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JNJ-2056 overview
JNJ-2056 is under development for the treatment of Alzheimer's disease and other tauopathies. It is a liposomal vaccine and is based on SupraAntigen technology platform. The vaccine candidate targets phospho-Tau (pTau). It is administered through intramuscular and parenteral route.
Johnson & Johnson Innovative Medicine overview
Johnson & Johnson Innovative Medicine (J&J Innovative), formerly Janssen Pharmaceuticals, is a healthcare company that develops and supplies prescription pharmaceutical products. It offers various types of medicines such as tablets, nasal sprays, oral solutions, injections, capsules, vaccines, and creams. J&J Innovative’s pipeline products include NJ-8177 (ARX517), JNJ-9401, JNJ-8343, and JNJ-6420 treats prostate cancer; JNJ-8377 for lymphoma; JNJ-0387, JNJ-2421 which treats solid tumors; JNJ-5322 for multiple myeloma and others. The company focuses on therapeutic areas of cardiovascular and metabolism, neuroscience, immunology, oncology and others. It offers its products under the brand AKEEGA, BALVERSA, CARVYKTI, DARZALEX, IMBRUVICA, LAZCLUZE and others. It is a subsidiary of Johnson & Johnson. J&J Innovative is headquartered in Titusville, New Jersey, the US.
For a complete picture of JNJ-2056’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.